Korean biotech IPO gives STIC 2x exit

The Seoul-based private equity and secondaries fund manager has exited its investment in Medy-Tox, generating a net IRR of 33.2% in two years.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this